Bengaluru-based MedGenome, India’s leading genomic diagnostics and research services company, has announced the launch of the country’s first CNS Tumour Methylation Classifier Test.
This diagnostic test can differentiate and classify over 90 classes of brain and central nervous system (CNS) tumours into accurate subtypes, enabling doctors to make optimal and accurate treatment decisions.
The test was unveiled in the presence of nearly 200 oncologists, neuro-onco surgeons and pathologists, researchers, and doctoral students at a precision oncology symposium in Mumbai, hosted by MedGenome jointly with Illumina, the global market leader in DNA sequencing and life sciences technologies.
Brain and CNS tumours are among the most complex cancers to diagnose. MedGenome’s new test complements traditional techniques, like Histology, by offering additional insights, as it studies the entire genome, identifying molecular changes and also predicting the tumor’s treatment response. The test uses DNA methylation profiling, a technique that examines chemical modifications across the genome, to create a unique profile of the tumour.
This profile is then compared to a global reference database to identify the exact tumuor type, enabling treatment planning tailored to the tumor’s molecular profile. The test has been found to be efficient even in cases that are rare or difficult to classify accurately. The results offer comprehensive support for more precise treatment decisions and guide personalised care.
MedGenome’s CNS Tumour Methylation Classifier Test aligns with the World Health Organization’s 2021 guidelines for CNS tumour classification. It delivers results within 21 days and includes WHO grade assignment, genome-wide copy number profiling, and key gene alteration detection in line with the best global practices.
